newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates

Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual